These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 24077924)
1. Donor factors similarly impact survival outcome after liver transplantation in hepatocellular carcinoma and non-hepatocellular carcinoma patients. Salgia RJ; Goodrich NP; Marrero JA; Volk ML Dig Dis Sci; 2014 Jan; 59(1):214-9. PubMed ID: 24077924 [TBL] [Abstract][Full Text] [Related]
2. Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China. Chen J; Yang Z; Gao F; Zhou Z; Chen J; Lu D; Wang K; Sui M; Wang Z; Guo W; Lyu G; Qi H; Cai J; Yang J; Zheng S; Xu X Cancer Biol Med; 2024 Feb; 21(4):347-62. PubMed ID: 38425217 [TBL] [Abstract][Full Text] [Related]
3. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Croome KP; Wall W; Chandok N; Beck G; Marotta P; Hernandez-Alejandro R Liver Transpl; 2013 Nov; 19(11):1214-23. PubMed ID: 23907778 [TBL] [Abstract][Full Text] [Related]
4. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. Dumitra S; Alabbad SI; Barkun JS; Dumitra TC; Coutsinos D; Metrakos PP; Hassanain M; Paraskevas S; Chaudhury P; Tchervenkov JI HPB (Oxford); 2013 Sep; 15(9):724-31. PubMed ID: 23490176 [TBL] [Abstract][Full Text] [Related]
6. Recipient obesity does not affect survival after deceased donor liver transplantation for hepatocellular carcinoma. A national retrospective cohort study in the United States. Ata N; Ayloo S; Tsung A; Molinari M HPB (Oxford); 2019 Jan; 21(1):67-76. PubMed ID: 30691592 [TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139 [TBL] [Abstract][Full Text] [Related]
8. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007 [TBL] [Abstract][Full Text] [Related]
9. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. Goldaracena N; Gorgen A; Doyle A; Hansen BE; Tomiyama K; Zhang W; Ghanekar A; Lilly L; Cattral M; Galvin Z; Selzner M; Bhat M; Selzner N; McGilvray I; Greig PD; Grant DR; Sapisochin G J Hepatol; 2019 Apr; 70(4):666-673. PubMed ID: 30630009 [TBL] [Abstract][Full Text] [Related]
10. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078 [TBL] [Abstract][Full Text] [Related]
11. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States. Berry K; Ioannou GN Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233 [TBL] [Abstract][Full Text] [Related]
13. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Park MS; Lee KW; Suh SW; You T; Choi Y; Kim H; Hong G; Yi NJ; Kwon CH; Joh JW; Lee SK; Suh KS Transplantation; 2014 Jan; 97(1):71-7. PubMed ID: 24056623 [TBL] [Abstract][Full Text] [Related]
14. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma. Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388 [TBL] [Abstract][Full Text] [Related]
15. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions. Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157 [TBL] [Abstract][Full Text] [Related]
16. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry. Taniguchi M Clin Transpl; 2012; ():41-65. PubMed ID: 23721009 [TBL] [Abstract][Full Text] [Related]
17. Impact of donor sex on hepatocellular carcinoma recurrence in liver transplantation after brain death. Nakamura T; Sasaki K; Kojima L; Teo R; Inaba Y; Yamamoto T; Kimura S; Dageforde LA; Yeh H; Elias N; Bozorgzadeh A; Kawai T; Markmann JF Clin Transplant; 2023 Aug; 37(8):e14989. PubMed ID: 37039506 [TBL] [Abstract][Full Text] [Related]